News for Huadong Medicine Co., Ltd (000963.SZ)

SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ('IMPACT'), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®）has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as 'Huadong Medicine'), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as 'SynerK') have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine has obtained the exclusive option, once exercised, for the right to develop, register, manufacture and commercialize the drug in Greater China.

Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems (”œR2”),

**media[471555]**

Get key insights and revenue forecasts from 2022-2032 with this comprehensive Cosmetic Surgery Market Report analysis.

Healthcare infrastructure development and increased funding are likely to drive demand for pharmerging....

The popularity of lip augmentation and cheek and chin correction among both genders is increasing, which is supporting the expansion of the dermal fillers...

SHANGHAI, July 16, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as 'Sanyou Bio') has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963, hereinafter referred to as 'Huadong Medicine'). The jointly developed ADC drug, designated as project number SYHD001, has successfully entered Phase I clinical trials. This important milestone not only signifies substantial progress in the collaboration between the two parties but also serves as a powerful testimony to the cutting-edge technology platform of Sanyou Bio.

EQS-News: Heidelberg Pharma AG / Key word(s): Annual Results Heidelberg Pharma announces financial figures and reports on su...

Feb 28, 2022 / 12:00PM GMTJan Schmidt-Brand - Heidelberg Pharma AG - CEO & CFO Hello, and [Ni hao] ladies and gentlemen. It's my great pleasure to welcome you t

Visiongain has published a new report entitled Orphan Drugs Market Report 2023-2033: Forecasts by Therapeutic Area (Cancer, Neurological Diseases,...

EQS-News: Heidelberg Pharma AG / Key word: Annual Report Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business 24.03.2023 / 07:11... | March 24, 2023

The Global Aesthetic Injectables Market Size was valued at USD 15.7 Billion in 2021 and the worldwide aesthetic injectables market size is expected to...

EQS-News: Heidelberg Pharma AG / Key word: Quarterly / Interim Statement Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022 13.10.2022 / 07:06... | October 13, 2022